1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabHemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasmRecruitingPhase 22025-12-10NCT06465433